Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 5.87B 5.13B 4.75B 4.36B 8.25B 566B 8.39B 56.62B 22.24B 276B 22.06B 21.57B 954B P/E 2026 *
66.6x
P/E 2027 * 34.9x
Enterprise Value 5.87B 5.13B 4.75B 4.36B 8.25B 566B 8.39B 56.62B 22.24B 276B 22.06B 21.57B 954B EV / Sales 2026 *
20.3x
EV / Sales 2027 * 15.6x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.06%
1 week-8.11%
Current month-6.21%
1 month+16.14%
3 months+32.79%
6 months+53.62%
Current year+56.79%
1 week 292.17
Extreme 292.17
316.42
1 month 245
Extreme 245
326.63
Current year 175.89
Extreme 175.89
326.63
1 year 129.55
Extreme 129.55
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 66 04/12/2022
Director of Finance/CFO 47 20/05/2015
Director of Finance/CFO 56 31/10/2022
Director TitleAgeSince
Chairman 76 28/02/2003
Director/Board Member 57 26/09/2006
Director/Board Member 66 28/02/2007
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Fiscal year

General Counsel

15,000 0.0748%
30/06/26 Others

Chief Financial Officer

17 0.0001%
30/06/26 Others

Chief Executive Officer

132 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-8.11%+128.69%+336.92% 5.87B
+1.08%-3.93%+48.03%+160.13% 1,031B
+1.19%-3.52%+51.70%+56.36% 595B
+4.21%+1.79%+33.48%+87.04% 431B
+0.42%-1.16%+29.43%+22.27% 326B
+1.03%-0.84%+29.58%+45.08% 277B
+0.49%-5.44%+21.00%+22.32% 263B
+1.59%+4.89%-22.56%-36.84% 224B
+3.70%+2.19%+24.27%+63.38% 193B
+3.49%+1.08%+24.08%+76.58% 164B
Average +1.81%-1.82%+36.77%+83.32% 351.02B
Weighted average by Cap. +1.81%-2.01%+34.86%+79.86%

Financials

2026 *2027 *
Net sales 290M 253M 234M 215M 407M 27.91B 414M 2.79B 1.1B 13.63B 1.09B 1.06B 47.05B 376M 328M 304M 279M 528M 36.21B 537M 3.62B 1.42B 17.68B 1.41B 1.38B 61.04B
Net income 94.48M 82.58M 76.37M 70.08M 133M 9.1B 135M 911M 358M 4.45B 355M 347M 15.35B 183M 160M 148M 136M 257M 17.64B 261M 1.76B 693M 8.61B 687M 672M 29.74B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Employees
47
Date Price Change Volume
16/07/26 US$296.45 +0.06% 241,733
15/07/26 US$296.26 -1.56% 291,126
14/07/26 US$300.97 -2.68% 649,076
13/07/26 US$309.25 -2.21% 245,725
10/07/26 US$316.24 -1.97% 148,576
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
296.45USD
Average target price
311.30USD
Spread / Average Target
+5.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock